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reduction in Cornell product (-150*849 vs -225a816 rnnwnsec, p=.OO4) and consequent 
oreater orevalence of Cornell product LVH (56.0 vs 48.1%. w.001). despite slicthtlv 
&eater decreases rn systolic (-31.0~0.0 vs -29.4el9.5 mm Hg,‘p=.Oll’) and diastolic BP 
(-17.8~11.1 vs -17.Oi10.2 mm Ha. o=.O17). After controllina for these baseline and in- _, 
study differences and for the drfferential treatment effect of losartan vs atenolol usrng 
analysrs of covariance, diabetics had significantly less reduction in Cornell product 
(adjusted mean change -115 vs -226 rnrnmw?c, p=O.O09) than nondiabetics. and, using 
multivariate logishc regression analysis, had a 1.31-fold greater risk of having ECG LVH 
by Cornell product at last study measurement (95% Cl 1.12-I .52, p<.OOl). 
Conclusion : Diabetic hypertensive patients have less regression of ECG LVH than non- 
diabetics. Further study will be needed to assess to what degree this accounts for their 
higher CVMM. 
IO:45 a.m. 
890-Z Blood Pressure, Weight, and Cholesterol 
Henry Buchwald James R. Bow, Stanley E. Williams, Phuong A. Nguyen, John P. 
Mans, University of Minnesota, Minneapolis, MN 
Background: To examine the blood pressure (BP), weight, and cholesterol data from the 
Program on the Surgical Control of the Hyperlipidemias (POSCH). Blood pressure (BP) 
reductions have been attributed to extra-lipid effects of statin drugs. In POSCH no statin 
drugs were employed and marked lipid reduction was achieved by the partial ileal bypass 
operation. 
Methods: Plasma total and low-density lipoprotein (LDL) cholesterol, BP, and body 
weight (as body mass index, BMI) rn POSCH patients at baseline and at B-years post- 
randomrzation were compared. 
Results: There were no statistically significant differences in mean systolic or diastolic BP 
between the control and intervention groups at baseline. At 5 years, however, statistically 
significant (p<O.O005) differences in mean systolrc and diastolic BP were found between 
the groups. Similarly, the differences between the groups in the BMI and the plasma total 
and LDL-cholesterol were not statistically significant at baseline, but were at 5 years 
(p<O.OOOl). By multivariate regression analyses, consistent, statistically significantly rela- 
tionships were found between BMI and BP (pcO.0001). In addition, for systolic BP, in the 
enhre POSCH population (n=838), a statistically significant relationship was found on 
regression analysis for the plasma total cholesterol (p<O.O13). 
Conclusions: POSCH is the only major lipidlatherosclerosrs trial to establish a relation- 
ship between cholesterol reduction and BP reduction without the need to implicate statin 
drugs’ extra-lipid effects. 
11:ooa.m. 
890-3 Adiposity-Independent Sympathetic Overactivity in 
African American Men 
Aamer Abbaa Paul Fad& Debbie Arbique, Zhongyun Wang, Meryem Tuncel, Ronald G. 
Victor, Wanpen Vongpatanasin, University of Texas Southwestern Medical Center, 
Dallas, TX 
Background: A large body of clinical investigation implicates an important role for the 
sympathetic newsus system in linking obesity with hypertension. However, most of the 
experimental support for this hypothesis has been dewed from strictly white cohorts. We 
recently demonstrated, in a cross-sectional study, that sympathetic nerve activity (SNA) 
is closely correlated with body mass index (BMI) rn Caucasrans and rn African American 
women, but, surprisingly, not in African American men. This dissociatron is explained by 
a uniformly high sympathetic nerve finng rate in African American men, regardless of adi- 
posity. 
Methods: To further test this ethnic- and gender- specific dissociahon, we now per- 
formed a prospecbve weight loss study comparing effects of hypocalonc diet on BMI and 
SNA in 11 obese African Amerrcan men and 6 obese African American women. SNA is 
measured with microelectrodes inserted selectively into muscle nerve fascicles of the 
peroneal nerves, before and 16 weeks after hypocaloric diet. 
Results: The mayor new finding is that, in normotensive obese African American men, 
the dietary-induced weight loss of 11.2iO 9 kg (from BMI of 32.7e1.2 to 29.Oil .l) had no 
effect on SNA (from baseline of 26r4 to 27i3 bursts/min, p = NS). In contrast, in young 
African American women, even a smaller amount of weight loss of 9.1+0.9 kg (from BMI 
of 33.2k2.5 to 29.9Q.7) was accompanied by reduction in SNA by more than 50% (from 
baseline of 22i3 to lot1 burstslmin, p = 0.02). These differences were not explained by 
dietary sodium content or urinary sodium excretion. 
Conclusion: These new data from our prospective study provide the strong support for a 
major adiposity-Independent sympathetic overactivity in African American men and adi- 
posity-related sympathetrc overactivity in African American women. The data suggest a 
potential neurophysiologic explanation for the clinical observation that weight gain does 
not predict incident hypertension in African Amencan men. 
11:15a.m. 
890-4 Relation of the Metabolic Syndrome to Cardiac Markers 
of Preclinical Disease: The Strong Heart Study 
Marcello Chinali, Richard B. Devereux, Barbara V. Howard, Mary J. Roman, Jonathan N. 
Bella, Jennifer E. Liu, Helaine E. Resnick, Elisa T. Lee, Lyle Best, Richard R. Fabsitz, 
Giovanni de Simone, Weill Medical College of Cornell University, New York, NY 
Background. Metabolic syndrome (MS) is linked to cardwascular risk. Recently pub- 
lished Adult Treatment Panel Ill (ATPIII) criteria provide a definition for diagnosis of MS. 
We analyzed the prevalence of cardiac markers of pre-clinical disease in MS participants 
and the impact of blood pressure on cardiac structure and function in the context of MS. 
Methods and Results. Left ventricular (LV) structure and function were examwad in 595 
non-diabetic SHS participants (31.5% men) with MS and in 809 normal participants 
(59.5% men). Among participants with MS, subgroups with or without non-optimal blood 
pressure @130/85mmHg) were compared. Participants with MS were older (60 vs 59 
years, ~0.05) and more often women (pcO.001). After controlling these covariates, MS 
participants exhibited higher LV diastolic diameter, LV mass, relative wall thickness, aor- 
tic root and left atrial dimensions and higher prevalence of LV hypertrophy (all p~.OOl). 
Ejection fraction was reduced fpzO.01) and LV relaxation (lower E/A ratio and higher 
mitral deceleration time) was prolonged (both pO.05). No differences were observed in 
BMI. body surface area, heart rate, plasma insulin or fasting glucose (all p=ns) between 
particrpants with the MS with or without non-optimal blood pressure However, in the con- 
text of MS, non-optimal blood pressure was associated with higher LV mass and hyper- 
trophy (both pa.OOl), and prolonged LV relaxation (lower E/A ratio and longer mitral 
deceleration time; both ~0.01) whereas cardiac findings in normotensive partrcrpants 
wrth the MS were similar to those in the non-MS participants. 
Conclusion. Abnormal LV geometry and function is related to MS by ATPIII definition 
only when blood pressure is elevated. Among particrpants with MS, those with non-opti- 
mal blood pressure have cardiac abnormalrties associated with impaired prognosis. 
II:30 a.m. 
890-5 Systolic Blood Pressure Control in Diabetics and 
Nondiabetics With Hypertension and Coronary Artery 
Disease 
Rhonda M. Coowr-DeHoff, Heather A. Bristol, Carl J. Pepine, University of Florida, 
Gainesville, FL 
Objective: To characterize systolic blood pressure (SBP) control in a population of dia- 
betic and nondiabetic patients with hypertension and coronary artery disease. Methods: 
An analysis was undertaken of 4,812 diabetics and 11.038 nondiabetics enrolled rn the 
INternational VErapamil/trandolapriI STudy (INVEST) and treated for 1 year. INVEST 
compares strategies containing either verapamil SR or atenolol and/or trandolapril and 
hydrochlorothiazide, relative to BP control (JNC VI goal of c130/<85 mmHg in diabetics 
and <140/<90 mmHg in nondiabetics and adverse outcomes. Results: A total of 4,237 
(68%) diabetics and 8,313 (75%) nondiabetrcs had SBP above the JNC VI goal at base- 
line despite antihypertensive treatment in 91% and 85%, respectively. Addihonally, at 
baseline, the percentage of diabetics and nondiabetics with SBP (rn mmHg) >169, 160- 
169, 150-159 and 140-149 were all similar. SBP and strategy drug use at 12 months are 
characterized in the table. At 12 months, diabetic patients recieved 3 strategy drugs twice 
as often as nondiabetics, whrch resulted in SBP reductions to either < 140 mmHg or < 
130 mmHg in similar percentages. Conclusion: Results indicate that after 12 months of 
treatment, 73% of all nondiabetics achieved JNC VI SBP goal of < 140 mmHg, but only 
43% of diabetics achieved JNC VI SBP goal of < 130 mmHg. These results confirm that it 
is more difficult to control SBP In diabetics if JNC VI goals are used, despite the use of 
more strategy drugs. 
Diabetics (n=4,812) Nondiabetics (n=ll.O38) 
Baseline SBP above JNC goal n (%) 4,237 (88) 8.312 (75) 
12MoSBPcl40mmHgn(%) 3,335 (69) 8,082 (73) 
12MoSBP<130mmHgn(%) 2,049 (43) 4,774 (43) 
Recerving 2 strategy drugs n (%) 1,776 (37) 4,451 (40) 
Receiving 3 strategy drugs n (%) 1.998 (42) 2,955 (27) 
11:45 a.m. 
890-6 Rofecoxib, but Not Celecoxib or Naproxen, Increases 
Mean 24-Hour Systolic Blood Pressure in Treated 
Hypertensive Patients With Osteoarthritis and Type 2 
Diabetes Mellitus 
James R. Sowers, William B. White, Bertram Pitt, Andrew Whelton, Lee Simon, Hein van 
Ingen, John Fort, State University of New York, Brooklyn, NY, Universrty of Connecticut 
School of Medicine, Farmington, CT 
Background: Non-specific NSAlDs are known to destabilize blood pressure (BP) in 
treated hypertensive patients. BP destabilization is of particular concern in Type 2 diabet- 
ics, given their increased risk of CV disease. Therefore, we compared the effects of the 
COX-2 specrfic inhibitors celecoxib (C) and rofecoxib (R) and the NSAID naproxen in 
patients with ACE inhibitor-treated hypertension (HTN), Type 2 DM, and osteoarthritis 
(ON. 
Methods: This was a multicenter, double-blind, randomized, 12 week study. Patients 
received C 200 mg QD (n=l36). R 25 mg QD (n=l38), or N 500 mg BID (n=l30). 24 hour 
ambulatory BP measurements (ABPM) were performed at baseline, and after 6 and 12 
weeks of therapy. The primary outcome measure was the mean change from baseline to 
week 6 of the average 24.hour systolic BP (SBP). Several validated arthritis efficacy 
assessments were performed at Weeks 6 and 12. A two-way ANOVA with invesbgational 
site and treaiment as factors were used to assess the drfferences in BP among the 3 
treatment groups. 
Results: The mean age of patients was 63: 60% were female. Mean SBP levels at base- 
line were 132, 132, and 134 mmHg for the C, R, and N groups, respectively. At week 6. R 
induced a significant increase in 24.hour SBP (+4.2 mmHg). whereas C and N did not (- 
0.1 and -0.8 mmHg respectively; P=.OO5). Treatment differences were as follows: C vs 
R (95% Cl) -3.8 (-6.4 to -1.2; P =.005); C “s N +O.l (-2.6 to 2.76; P =.956); R “S N +3.9 
(1.2 to 6.6; P=.OO5). Results for ambulatory SBP at Week 12 were comparable to Week 
6. Comparative doses of these drugs were equally effective in improvement of OA: 
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change m total WOMAC score (-14, -15, and -13; P =.4) and WOMAC pain subscale 
score (-13, -16, and -13; P=.5) at Week 6 were similar for all 3 treatments; comparable 
results were noted at Week 12. 
Conclusion: Rofecoxib. but not celecoxib 01 naproxen, all at doses providing equal effi- 
cacy, induced a significant increase in 24 hour ambulatory SBP in hypertensive patients 
with OA and Type 2 DM. These data confirm that celecoxib 200 mg QD has a more 
favorable BP side effect profile than rofecoxib 25 mg QD in high risk patients with hyper- 
tension and Type 2 diabetes using ACE inhibitors. 
Disclosure: Sponsored by Pharmacia Corporation and Pfizer Inc. 
